APYX — Apyx Medical Income Statement
0.000.00%
Last trade - 00:00
- $50.58m
- $40.41m
- $52.35m
- 34
- 45
- 36
- 32
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 28.2 | 27.7 | 48.5 | 44.5 | 52.3 |
Cost of Revenue | |||||
Gross Profit | 19.1 | 17.5 | 33.6 | 29.1 | 33.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 49.1 | 47.8 | 63 | 68.1 | 72.7 |
Operating Profit | -20.9 | -20.1 | -14.4 | -23.6 | -20.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19.8 | -19.4 | -14.8 | -22.9 | -21.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -19.7 | -15.6 | -15.2 | -23.3 | -18.9 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -19.7 | -11.9 | -15.2 | -23.2 | -18.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -19.7 | -11.9 | -15.2 | -23.2 | -18.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.578 | -0.455 | -0.442 | -0.672 | -0.533 |